But if I knew how to manage my portfolio safer and smarter than most hedge fund managers, I could realistically grow my wealth.
Leveraged loan issuance remains depressed, though not as badly depressed as the high yield bond market
The weekly leveraged loan issuance for the week ended June 28, 2013, was $9.9 billion across 15 deals, which is on the lower end of the c. $9.5-13.5 billion weekly volumes we’ve seen over the past month. While leveraged loans saw a decrease of ~30-40% of weekly volumes, the high yield bond volume dropped ~75%.
Issuance overwhelmed by Valeant deal
The Valeant Pharmaceuticals deal accounted for $3.2 billion, which is the largest term loan since the Heinz transaction. The deal included another $3.2 billion in high yield bonds, an $850 million Term Loan A (a syndicated bank loan), and another $2.3 billion in equity. The company will use the proceeds to buy Bausch & Lomb. The original price talk was L+325-350 basis points, but ended up pricing 50 basis points higher, with an additional 1% discount.
The deal certainly overstretched the market, and bankers advising other in-market issues likely decided to postpone pricing to avoid competing with Valeant. Investors pushed back hard on terms, causing 16 deals in market to revise to a higher price talk and get rid of any cov-lite1 structures in favor of loans with complete maintenance covenants2.
Loans close higher
The leveraged loan market closed marginally higher for the week—approximately 0.5% higher according to the LCDX index—yet the leveraged loan ETFs (exchange-traded funds SNLN and BKLN) didn’t increase as much. However, this week, the ETFs are performing much better.
In the medium term, interest rates will move higher and spreads may stop widening (spreads widened 50 basis points in June), which will benefit loans. On the other hand, the asset may lose its appeal to other asset classes such as equities if the market recovers, which will reduce price support.
© 2013 Market Realist, Inc.